Immune escape from NY-ESO-1-specific T cell therapy via loss of heterozygosity in the MHC

Adoptive immunotherapy of tumors with T cells specific for the cancer-testis antigen NY-ESO-1 has shown great promise in preclinical models and in early stage clinical trials. Tumor persistence or recurrence after NY-ESO-1-specific therapy occurs, however, and the mechanisms of recurrence remain poo...

Descripción completa

Detalles Bibliográficos
Autores principales: Klippel, Zandra K., Chou, Jeffrey, Towlerton, Andrea M., Voong, Lilien N., Robbins, Paul, Bensinger, William I., Warren, Edus H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040020/
https://www.ncbi.nlm.nih.gov/pubmed/24451117
http://dx.doi.org/10.1038/gt.2013.87

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4040020/
https://www.ncbi.nlm.nih.gov/pubmed/24451117
http://dx.doi.org/10.1038/gt.2013.87

Ejemplares similares